{"id":946507,"date":"2026-03-24T10:25:05","date_gmt":"2026-03-24T14:25:05","guid":{"rendered":"https:\/\/www.marketnewsdesk.com\/index.php\/inmune-bio-inc-to-report-year-end-2025-financial-results-and-provide-corporate-update-on-monday-march-30th\/"},"modified":"2026-03-24T10:25:05","modified_gmt":"2026-03-24T14:25:05","slug":"inmune-bio-inc-to-report-year-end-2025-financial-results-and-provide-corporate-update-on-monday-march-30th","status":"publish","type":"post","link":"https:\/\/www.marketnewsdesk.com\/index.php\/inmune-bio-inc-to-report-year-end-2025-financial-results-and-provide-corporate-update-on-monday-march-30th\/","title":{"rendered":"INmune Bio Inc. to Report Year End 2025 Financial Results and Provide Corporate Update on Monday, March 30th."},"content":{"rendered":"<div class=\"mw_release\">\n<p>\n        <i>Management to host conference call and webcast at 4:30 pm ET on that day<\/i>\n      <\/p>\n<p>Boca Raton, Florida, March  24, 2026  (GLOBE NEWSWIRE) &#8212;  <a href=\"https:\/\/www.globenewswire.com\/Tracker?data=tBJmHJAblwr7Uaan31A2FOrQSt40B-o9YzWeTlxLcoWu-HXmjj9g_HszthKu5X1DgmVZ6Zz0lDFBJMVytGybacZWphWwORVBYCvREzEhCOk=\" rel=\"nofollow\" target=\"_blank\">INmune Bio Inc<\/a>. (NASDAQ: INMB) (the \u201cCompany\u201d), a clinical-stage inflammation and immunology company, today announced that it will host a conference call on Monday, March 30th, 2026 at 4:30pm EDT to discuss results for its year ended December 31, 2025, and to provide a corporate update.\u00a0<\/p>\n<p>\n        <b><br \/>\n          <u>Conference Call Information<\/u><br \/>\n        <\/b>\n      <\/p>\n<p>To participate in this event, dial approximately 5 to 10 minutes before the beginning of the call. Please ask for the INmune Bio First Quarter Conference Call when reaching the operator.<\/p>\n<p>Date: March 30<sup>th<\/sup>, 2026<\/p>\n<p>Time: 4:30 PM Eastern Time<\/p>\n<p>Participant Dial-in: 1-800-343-4136 Participant Dial-in (international): +1-203-518-9843<\/p>\n<p>Conference ID: INMUNE<\/p>\n<p align=\"left\">A live audio webcast of the call can be accessed using this link or clicking <a href=\"https:\/\/www.globenewswire.com\/Tracker?data=1vTNsNVazJk6pE-tcKQ43-y1BOhVOtPlf_smPq56dgxK7PAaEl4nEt4FJZ7UtqCYNrE1-czC_H5CT-0LKSwKVWz97xwe7Zv8-JxLjk5BYDjkR0_UUl_ImYE0db0e9uZhp-hMR_-PbkPXLJMBby3x9g==\" rel=\"nofollow\" target=\"_blank\">here<\/a>:<br \/><a href=\"https:\/\/www.globenewswire.com\/Tracker?data=OursdO6gWJIeAdkp7H7_vOOZO12pDoleoyJsF8P7hoLAMhRaDxrB2cJOPjFwTOzvC29_Z3QYwZSyt7Ge9cotmF1u2LP05BzR8LePao957s2LVfzwswK857TqT6b9QlvUj5HEQ37SfCg6RJHC20nxPH7_7lKzjYXseYJEN9zzBe8prEvK71U0LxGMzQ06ahhG95yB9sK2v6fqQWCehsLiiJy_mUeeyjKfHGl9mk7nKOY=\" rel=\"nofollow\" target=\"_blank\">https:\/\/viavid.webcasts.com\/starthere.jsp?ei=1748958&amp;tp_key=96ca7c85d7<\/a>\u00a0<\/p>\n<p>A replay will be available approximately 3 hours after the call through April 13, 2026 by dialing 1-844-512-2921 or 1-412-317-6671 (international) and entering PIN no. 11160807.<\/p>\n<p align=\"justify\">\n        <b>About INmune Bio Inc.<\/b>\n      <\/p>\n<p align=\"justify\">INmune Bio Inc. is a publicly traded (NASDAQ: INMB), clinical-stage biotechnology company focused on developing treatments that target the innate immune system to fight disease. INmune Bio has three product platforms: (1) CORDStrom\u2122, a proprietary pooled, allogeneic, human umbilical cord-derived mesenchymal Stromal\/Stem cell (hucMSCs) platform that recently completed a blinded randomized trial in recessive dystrophic epidermolysis bullosa; (2) XPro\u2122, a Dominant-Negative Tumor Necrosis Factor (DN-TNF) product platform designed to selectively neutralize soluble TNF, a key driver of inflammation and innate immune dysfunction; and (3) INKmune\u00ae, a cell-based medicine designed to prime a patient\u2019s natural killer cells to eliminate minimal residual disease in patients with cancer.\u00a0 To learn more, please visit <a href=\"https:\/\/www.globenewswire.com\/Tracker?data=dHT4NuFIhxntzTVfugq9lMAl9bkLR20AZZgirsZpKcKDOyfYNzIzFofsaj-MtuGPm2Abo7cZGjhMib9JAkmKy_vMu22et2AuEII4TYMhphYePiAnuGCVB9g7_KoU124-MloySvb5kAtwPKYGk2nBoJ0guxIhbELiDf55mHjrUwDZmtXG9Psk3v3wn8HKEREyp3T0JbKet-fDoTS_i0jRmnb7Vnq8q0uDFlMNYH823H_VSIXeBiOF-_OPSLfAejYblUh1DJBmz5XmnsHv0oflHA==\" rel=\"nofollow\" target=\"_blank\">www.inmunebio.com<\/a>.<\/p>\n<p align=\"justify\">\n        <b>Forward Looking Statements<\/b>\n      <\/p>\n<p align=\"justify\">Clinical trials are in early stages, and there is no assurance that any specific outcome will be achieved. Any statements contained in this press release related to the development or commercialization of product candidates and other business and financial matters, including without limitation, trial results and data, including trial results, timing of key milestones, future plans or expectations, and the prospects for receiving regulatory approval or commercializing or selling any product or drug candidates, may constitute forward-looking statements as that term is defined in the Private Securities Litigation Reform Act of 1995. Any forward-looking statements contained herein are based on current expectations but are subject to several risks and uncertainties. Actual results and the timing of certain events and circumstances may differ materially from those described by the forward-looking statements because of these risks and uncertainties. CORDstrom\u2122, XPro1595\u2122 (XPro\u2122, pegipanermin), and INKmune\u00ae\u2122 have either finished clinical trials, are still in clinical trials or are preparing to start clinical trials and have not been approved by the US Food and Drug Administration (FDA), the UK MHRA or any regulatory body and there cannot be any assurance that they will be approved by the FDA, the UK MHRA or any regulatory body or that any specific results will be achieved. The factors that could cause actual future results to differ materially from current expectations include, but are not limited to, risks and uncertainties relating to the Company\u2019s ability to produce more drug for clinical trials; the availability of substantial additional funding for the Company to continue its operations and to conduct research and development, clinical studies and future product commercialization; and the Company\u2019s business, research, product development, regulatory approval, marketing and distribution plans and strategies. These and other factors are identified and described in more detail in the Company\u2019s filings with the Securities and Exchange Commission, including the Company\u2019s Annual Report on Form 10-K, the Company\u2019s Quarterly Reports on Form 10-Q and the Company\u2019s Current Reports on Form 8-K. The Company assumes no obligation to update any forward-looking statements to reflect any event or circumstance that may arise after the date of this release.<\/p>\n<p>\n        <b>Company Contact: <\/b>\n      <\/p>\n<p>David Moss<br \/>Chief Executive Officer<br \/>(561) 710-0512<br \/><a href=\"https:\/\/www.globenewswire.com\/Tracker?data=z-1YfpA13MG0jLSbWqIdG1xbQUgW9i8WPWoTu2kGxK4BDY43XubYBYqmbp70UMoeRpXBLTV86ve_KWa3I-IhECWNo-nra132QwK1FOmkjZQ=\" rel=\"nofollow\" target=\"_blank\">info@inmunebio.com<\/a><\/p>\n<p>Daniel Carlson<br \/>Head of Investor Relations<br \/>(415) 509-4590<br \/><a href=\"https:\/\/www.globenewswire.com\/Tracker?data=PAIPayxr7LYfeqBTjNuanHVLQh4MmRiZEZA6FBSO07fVE1rhvHVwLRNoOviuHBm2y1E7Lu0OsqQSjITcTjEuzRo8lCcc3Ka5HebzJBUfNh4=\" rel=\"nofollow\" target=\"_blank\">dcarlson@inmunebio.com<\/a><\/p>\n<p>      <img decoding=\"async\" alt=\"\" class=\"__GNW8366DE3E__IMG\" src=\"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=OTY3Njk3MCM3NDk5MzEyIzUwMDA2ODMyNA==\" \/><br \/>\n      <br \/>\n      <img decoding=\"async\" alt=\"\" src=\"https:\/\/ml.globenewswire.com\/media\/MTQ1NjBjMGEtMWUwMC00MGRkLTk2NjUtZGIyNTU2NjdiNzA3LTUwMDA2ODMyNC0yMDI2LTAzLTI0LWVu\/tiny\/INmune-Bio-Inc-.png\" \/>\n    <\/div>\n<div class=\"mw_contactinfo\"><\/div>\n","protected":false},"excerpt":{"rendered":"<p>Management to host conference call and webcast at 4:30 pm ET on that day Boca Raton, Florida, March 24, 2026 (GLOBE NEWSWIRE) &#8212; INmune Bio Inc. (NASDAQ: INMB) (the \u201cCompany\u201d), a clinical-stage inflammation and immunology company, today announced that it will host a conference call on Monday, March 30th, 2026 at 4:30pm EDT to discuss results for its year ended December 31, 2025, and to provide a corporate update.\u00a0 Conference Call Information To participate in this event, dial approximately 5 to 10 minutes before the beginning of the call. Please ask for the INmune Bio First Quarter Conference Call when reaching the operator. Date: March 30th, 2026 Time: 4:30 PM Eastern Time Participant Dial-in: 1-800-343-4136 Participant Dial-in (international): +1-203-518-9843 Conference &hellip; <\/p>\n<p class=\"link-more\"><a href=\"https:\/\/www.marketnewsdesk.com\/index.php\/inmune-bio-inc-to-report-year-end-2025-financial-results-and-provide-corporate-update-on-monday-march-30th\/\" class=\"more-link\">Continue reading<span class=\"screen-reader-text\"> &#8220;INmune Bio Inc. to Report Year End 2025 Financial Results and Provide Corporate Update on Monday, March 30th.&#8221;<\/span><\/a><\/p>\n","protected":false},"author":2,"featured_media":0,"comment_status":"closed","ping_status":"closed","sticky":false,"template":"","format":"standard","meta":{"footnotes":""},"categories":[],"tags":[],"class_list":["post-946507","post","type-post","status-publish","format-standard","hentry"],"yoast_head":"<!-- This site is optimized with the Yoast SEO plugin v28.9 - https:\/\/yoast.com\/product\/yoast-seo-wordpress\/ -->\n<title>INmune Bio Inc. to Report Year End 2025 Financial Results and Provide Corporate Update on Monday, March 30th. - Market Newsdesk<\/title>\n<meta name=\"robots\" content=\"index, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1\" \/>\n<link rel=\"canonical\" href=\"https:\/\/www.marketnewsdesk.com\/index.php\/inmune-bio-inc-to-report-year-end-2025-financial-results-and-provide-corporate-update-on-monday-march-30th\/\" \/>\n<meta property=\"og:locale\" content=\"en_US\" \/>\n<meta property=\"og:type\" content=\"article\" \/>\n<meta property=\"og:title\" content=\"INmune Bio Inc. to Report Year End 2025 Financial Results and Provide Corporate Update on Monday, March 30th. - Market Newsdesk\" \/>\n<meta property=\"og:description\" content=\"Management to host conference call and webcast at 4:30 pm ET on that day Boca Raton, Florida, March 24, 2026 (GLOBE NEWSWIRE) &#8212; INmune Bio Inc. (NASDAQ: INMB) (the \u201cCompany\u201d), a clinical-stage inflammation and immunology company, today announced that it will host a conference call on Monday, March 30th, 2026 at 4:30pm EDT to discuss results for its year ended December 31, 2025, and to provide a corporate update.\u00a0 Conference Call Information To participate in this event, dial approximately 5 to 10 minutes before the beginning of the call. Please ask for the INmune Bio First Quarter Conference Call when reaching the operator. Date: March 30th, 2026 Time: 4:30 PM Eastern Time Participant Dial-in: 1-800-343-4136 Participant Dial-in (international): +1-203-518-9843 Conference &hellip; Continue reading &quot;INmune Bio Inc. to Report Year End 2025 Financial Results and Provide Corporate Update on Monday, March 30th.&quot;\" \/>\n<meta property=\"og:url\" content=\"https:\/\/www.marketnewsdesk.com\/index.php\/inmune-bio-inc-to-report-year-end-2025-financial-results-and-provide-corporate-update-on-monday-march-30th\/\" \/>\n<meta property=\"og:site_name\" content=\"Market Newsdesk\" \/>\n<meta property=\"article:published_time\" content=\"2026-03-24T14:25:05+00:00\" \/>\n<meta property=\"og:image\" content=\"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=OTY3Njk3MCM3NDk5MzEyIzUwMDA2ODMyNA==\" \/>\n<meta name=\"author\" content=\"Newsdesk\" \/>\n<meta name=\"twitter:card\" content=\"summary_large_image\" \/>\n<meta name=\"twitter:label1\" content=\"Written by\" \/>\n\t<meta name=\"twitter:data1\" content=\"Newsdesk\" \/>\n\t<meta name=\"twitter:label2\" content=\"Est. reading time\" \/>\n\t<meta name=\"twitter:data2\" content=\"3 minutes\" \/>\n<script type=\"application\/ld+json\" class=\"yoast-schema-graph\">{\"@context\":\"https:\\\/\\\/schema.org\",\"@graph\":[{\"@type\":\"Article\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/inmune-bio-inc-to-report-year-end-2025-financial-results-and-provide-corporate-update-on-monday-march-30th\\\/#article\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/inmune-bio-inc-to-report-year-end-2025-financial-results-and-provide-corporate-update-on-monday-march-30th\\\/\"},\"author\":{\"name\":\"Newsdesk\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#\\\/schema\\\/person\\\/482f27a394d4fda80ecb5499e519d979\"},\"headline\":\"INmune Bio Inc. to Report Year End 2025 Financial Results and Provide Corporate Update on Monday, March 30th.\",\"datePublished\":\"2026-03-24T14:25:05+00:00\",\"mainEntityOfPage\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/inmune-bio-inc-to-report-year-end-2025-financial-results-and-provide-corporate-update-on-monday-march-30th\\\/\"},\"wordCount\":683,\"image\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/inmune-bio-inc-to-report-year-end-2025-financial-results-and-provide-corporate-update-on-monday-march-30th\\\/#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/www.globenewswire.com\\\/newsroom\\\/ti?nf=OTY3Njk3MCM3NDk5MzEyIzUwMDA2ODMyNA==\",\"inLanguage\":\"en-US\"},{\"@type\":\"WebPage\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/inmune-bio-inc-to-report-year-end-2025-financial-results-and-provide-corporate-update-on-monday-march-30th\\\/\",\"url\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/inmune-bio-inc-to-report-year-end-2025-financial-results-and-provide-corporate-update-on-monday-march-30th\\\/\",\"name\":\"INmune Bio Inc. to Report Year End 2025 Financial Results and Provide Corporate Update on Monday, March 30th. - Market Newsdesk\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#website\"},\"primaryImageOfPage\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/inmune-bio-inc-to-report-year-end-2025-financial-results-and-provide-corporate-update-on-monday-march-30th\\\/#primaryimage\"},\"image\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/inmune-bio-inc-to-report-year-end-2025-financial-results-and-provide-corporate-update-on-monday-march-30th\\\/#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/www.globenewswire.com\\\/newsroom\\\/ti?nf=OTY3Njk3MCM3NDk5MzEyIzUwMDA2ODMyNA==\",\"datePublished\":\"2026-03-24T14:25:05+00:00\",\"author\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#\\\/schema\\\/person\\\/482f27a394d4fda80ecb5499e519d979\"},\"breadcrumb\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/inmune-bio-inc-to-report-year-end-2025-financial-results-and-provide-corporate-update-on-monday-march-30th\\\/#breadcrumb\"},\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"ReadAction\",\"target\":[\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/inmune-bio-inc-to-report-year-end-2025-financial-results-and-provide-corporate-update-on-monday-march-30th\\\/\"]}]},{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/inmune-bio-inc-to-report-year-end-2025-financial-results-and-provide-corporate-update-on-monday-march-30th\\\/#primaryimage\",\"url\":\"https:\\\/\\\/www.globenewswire.com\\\/newsroom\\\/ti?nf=OTY3Njk3MCM3NDk5MzEyIzUwMDA2ODMyNA==\",\"contentUrl\":\"https:\\\/\\\/www.globenewswire.com\\\/newsroom\\\/ti?nf=OTY3Njk3MCM3NDk5MzEyIzUwMDA2ODMyNA==\"},{\"@type\":\"BreadcrumbList\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/inmune-bio-inc-to-report-year-end-2025-financial-results-and-provide-corporate-update-on-monday-march-30th\\\/#breadcrumb\",\"itemListElement\":[{\"@type\":\"ListItem\",\"position\":1,\"name\":\"Home\",\"item\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/\"},{\"@type\":\"ListItem\",\"position\":2,\"name\":\"INmune Bio Inc. to Report Year End 2025 Financial Results and Provide Corporate Update on Monday, March 30th.\"}]},{\"@type\":\"WebSite\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#website\",\"url\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/\",\"name\":\"Market Newsdesk\",\"description\":\"Latest Business News in Real Time\",\"potentialAction\":[{\"@type\":\"SearchAction\",\"target\":{\"@type\":\"EntryPoint\",\"urlTemplate\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/?s={search_term_string}\"},\"query-input\":{\"@type\":\"PropertyValueSpecification\",\"valueRequired\":true,\"valueName\":\"search_term_string\"}}],\"inLanguage\":\"en-US\"},{\"@type\":\"Person\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#\\\/schema\\\/person\\\/482f27a394d4fda80ecb5499e519d979\",\"name\":\"Newsdesk\",\"image\":{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g\",\"url\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g\",\"contentUrl\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g\",\"caption\":\"Newsdesk\"},\"url\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/author\\\/newsdesk\\\/\"}]}<\/script>\n<!-- \/ Yoast SEO plugin. -->","yoast_head_json":{"title":"INmune Bio Inc. to Report Year End 2025 Financial Results and Provide Corporate Update on Monday, March 30th. - Market Newsdesk","robots":{"index":"index","follow":"follow","max-snippet":"max-snippet:-1","max-image-preview":"max-image-preview:large","max-video-preview":"max-video-preview:-1"},"canonical":"https:\/\/www.marketnewsdesk.com\/index.php\/inmune-bio-inc-to-report-year-end-2025-financial-results-and-provide-corporate-update-on-monday-march-30th\/","og_locale":"en_US","og_type":"article","og_title":"INmune Bio Inc. to Report Year End 2025 Financial Results and Provide Corporate Update on Monday, March 30th. - Market Newsdesk","og_description":"Management to host conference call and webcast at 4:30 pm ET on that day Boca Raton, Florida, March 24, 2026 (GLOBE NEWSWIRE) &#8212; INmune Bio Inc. (NASDAQ: INMB) (the \u201cCompany\u201d), a clinical-stage inflammation and immunology company, today announced that it will host a conference call on Monday, March 30th, 2026 at 4:30pm EDT to discuss results for its year ended December 31, 2025, and to provide a corporate update.\u00a0 Conference Call Information To participate in this event, dial approximately 5 to 10 minutes before the beginning of the call. Please ask for the INmune Bio First Quarter Conference Call when reaching the operator. Date: March 30th, 2026 Time: 4:30 PM Eastern Time Participant Dial-in: 1-800-343-4136 Participant Dial-in (international): +1-203-518-9843 Conference &hellip; Continue reading \"INmune Bio Inc. to Report Year End 2025 Financial Results and Provide Corporate Update on Monday, March 30th.\"","og_url":"https:\/\/www.marketnewsdesk.com\/index.php\/inmune-bio-inc-to-report-year-end-2025-financial-results-and-provide-corporate-update-on-monday-march-30th\/","og_site_name":"Market Newsdesk","article_published_time":"2026-03-24T14:25:05+00:00","og_image":[{"url":"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=OTY3Njk3MCM3NDk5MzEyIzUwMDA2ODMyNA==","type":"","width":"","height":""}],"author":"Newsdesk","twitter_card":"summary_large_image","twitter_misc":{"Written by":"Newsdesk","Est. reading time":"3 minutes"},"schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"Article","@id":"https:\/\/www.marketnewsdesk.com\/index.php\/inmune-bio-inc-to-report-year-end-2025-financial-results-and-provide-corporate-update-on-monday-march-30th\/#article","isPartOf":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/inmune-bio-inc-to-report-year-end-2025-financial-results-and-provide-corporate-update-on-monday-march-30th\/"},"author":{"name":"Newsdesk","@id":"https:\/\/www.marketnewsdesk.com\/#\/schema\/person\/482f27a394d4fda80ecb5499e519d979"},"headline":"INmune Bio Inc. to Report Year End 2025 Financial Results and Provide Corporate Update on Monday, March 30th.","datePublished":"2026-03-24T14:25:05+00:00","mainEntityOfPage":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/inmune-bio-inc-to-report-year-end-2025-financial-results-and-provide-corporate-update-on-monday-march-30th\/"},"wordCount":683,"image":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/inmune-bio-inc-to-report-year-end-2025-financial-results-and-provide-corporate-update-on-monday-march-30th\/#primaryimage"},"thumbnailUrl":"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=OTY3Njk3MCM3NDk5MzEyIzUwMDA2ODMyNA==","inLanguage":"en-US"},{"@type":"WebPage","@id":"https:\/\/www.marketnewsdesk.com\/index.php\/inmune-bio-inc-to-report-year-end-2025-financial-results-and-provide-corporate-update-on-monday-march-30th\/","url":"https:\/\/www.marketnewsdesk.com\/index.php\/inmune-bio-inc-to-report-year-end-2025-financial-results-and-provide-corporate-update-on-monday-march-30th\/","name":"INmune Bio Inc. to Report Year End 2025 Financial Results and Provide Corporate Update on Monday, March 30th. - Market Newsdesk","isPartOf":{"@id":"https:\/\/www.marketnewsdesk.com\/#website"},"primaryImageOfPage":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/inmune-bio-inc-to-report-year-end-2025-financial-results-and-provide-corporate-update-on-monday-march-30th\/#primaryimage"},"image":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/inmune-bio-inc-to-report-year-end-2025-financial-results-and-provide-corporate-update-on-monday-march-30th\/#primaryimage"},"thumbnailUrl":"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=OTY3Njk3MCM3NDk5MzEyIzUwMDA2ODMyNA==","datePublished":"2026-03-24T14:25:05+00:00","author":{"@id":"https:\/\/www.marketnewsdesk.com\/#\/schema\/person\/482f27a394d4fda80ecb5499e519d979"},"breadcrumb":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/inmune-bio-inc-to-report-year-end-2025-financial-results-and-provide-corporate-update-on-monday-march-30th\/#breadcrumb"},"inLanguage":"en-US","potentialAction":[{"@type":"ReadAction","target":["https:\/\/www.marketnewsdesk.com\/index.php\/inmune-bio-inc-to-report-year-end-2025-financial-results-and-provide-corporate-update-on-monday-march-30th\/"]}]},{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/www.marketnewsdesk.com\/index.php\/inmune-bio-inc-to-report-year-end-2025-financial-results-and-provide-corporate-update-on-monday-march-30th\/#primaryimage","url":"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=OTY3Njk3MCM3NDk5MzEyIzUwMDA2ODMyNA==","contentUrl":"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=OTY3Njk3MCM3NDk5MzEyIzUwMDA2ODMyNA=="},{"@type":"BreadcrumbList","@id":"https:\/\/www.marketnewsdesk.com\/index.php\/inmune-bio-inc-to-report-year-end-2025-financial-results-and-provide-corporate-update-on-monday-march-30th\/#breadcrumb","itemListElement":[{"@type":"ListItem","position":1,"name":"Home","item":"https:\/\/www.marketnewsdesk.com\/"},{"@type":"ListItem","position":2,"name":"INmune Bio Inc. to Report Year End 2025 Financial Results and Provide Corporate Update on Monday, March 30th."}]},{"@type":"WebSite","@id":"https:\/\/www.marketnewsdesk.com\/#website","url":"https:\/\/www.marketnewsdesk.com\/","name":"Market Newsdesk","description":"Latest Business News in Real Time","potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"https:\/\/www.marketnewsdesk.com\/?s={search_term_string}"},"query-input":{"@type":"PropertyValueSpecification","valueRequired":true,"valueName":"search_term_string"}}],"inLanguage":"en-US"},{"@type":"Person","@id":"https:\/\/www.marketnewsdesk.com\/#\/schema\/person\/482f27a394d4fda80ecb5499e519d979","name":"Newsdesk","image":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/secure.gravatar.com\/avatar\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g","url":"https:\/\/secure.gravatar.com\/avatar\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g","contentUrl":"https:\/\/secure.gravatar.com\/avatar\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g","caption":"Newsdesk"},"url":"https:\/\/www.marketnewsdesk.com\/index.php\/author\/newsdesk\/"}]}},"_links":{"self":[{"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/posts\/946507","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/users\/2"}],"replies":[{"embeddable":true,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/comments?post=946507"}],"version-history":[{"count":0,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/posts\/946507\/revisions"}],"wp:attachment":[{"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/media?parent=946507"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/categories?post=946507"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/tags?post=946507"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}